Table 2.

Animal experiments in mice using [⁶⁸Ga]Ga-PSMA-11 (Glu-NH-CO-NH-Lys(Ahx)-HBED-CC) or a similar PSMA-specific tracer in comparison to the present HET-CAM study (mean ± SD). The activity concentration ratios have been calculated based on the published data.

Ligand	Tumor Accumulation [%IA/g]			Activity Concentration Ratio (PSMA+/PSMA−)	Incubation Time [h]	Ref.
	LNCaP	LNCaP C4-2	PC-3
68Ga-PSMA-11	-	9.27 ± 5.61	4.02 ± 3.78	2.3; (4.0) †	1	HET-CAM §
68Ga-PSMA-11	6.95 ± 1.31	-	1.45 ± 0.41	4.8; (4.9) †	1	HET-CAM §
68Ga-PSMA-11	7.70 ± 1.45	-	1.30 ± 0.12	5.9	1	[41]
68Ga-PSMA-11	4.89 ± 1.34	-	1.30 ± 0.12	3.8	1	[42]
68Ga-PSMA-11	7.28 ± 0.82	-	1.21 ± 0.07	6.0	1	[53]
68Ga-PSMA-11	5.89 ± 2.82	-	-	-	1	[54]
68Ga-PSMA-11	12.75 ± 2.49	-	-	-	1	[55]
68Ga-PSMA-11	8.91 ± 0.86	-	-	-	1	[56]
68Ga-PSMA-11	8.42 ± 1.40	-	-	-	1	[57]
68Ga-PSMA-11	7.19 ± 0.86	-	-	-	1	[57]
68Ga-PSMA-11	8.20 ± 2.44	-	-	-	1	[57]
68Ga-PSMA-11	8.67 ± 1.97	-	-	-	1	[57]
68Ga-PSMA-11-Dimer	8.22 ± 1.78	-	0.93 ± 0.53	8.8	1	[42]
18F-PSMA-11	55.7 ± 11.8	-	3.1 ± 0.9	18.0	6	[58]
18F-PSMA-1007	8.04 ± 2.39	-	1.05 ± 0.11	7.7	1	[59]
[11C]DCMC	8.73 ± 0.73	-	1.65 ± 0.29	5.3	0.5	[60]
[11C]DCIT	5.07 ± 1.02	-	1.78 ± 0.63	2.8	0.5	[60]
68Ga-HE0	2.38 ± 0.05	-	0.84 ± 0.18	2.8	1	[54]
68Ga-HE1	2.41 ± 1.24	-	2.67 ± 1.25	0.9	1	[54]
68Ga-HE2	10.66 ± 4.19	-	1.99 ± 0.40	2.5	1	[54]
68Ga-HE3	3.22 ± 0.22	-	1.66 ± 0.41	1.9	1	[54]
203Pb-PSMA-CA012	-	8.4 ± 3.7	-	-	1	[61]
DUPA-99mTc	11.2	-	-	-	4	[62]
68Ga-CHX-A″-DTPA conjugate	~3 *	-	-	-	1	[63]
68Ga-CHX-A″-DOTA conjugate	~7 *	-	-	-	1	[63]
68Ga-PSMA-617	8.47 ± 4.09	-	-	-	1	[64]
177Lu-PSMA-617	11.20 ± 4.17	-	-	-	1	[64]
64Cu-PSMA-617	-	-	3.47 ± 0.48	-	24	[65]

† ratios of the mean; (mean of the ratios); § present study; * values estimated from diagram.